Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $251.5501, but opened at $232.50. Genmab A/S shares last traded at $232.50, with a volume of 254 shares trading hands.
Genmab A/S Price Performance
The company’s 50 day moving average price is $265.53 and its 200-day moving average price is $295.29. The stock has a market cap of $14.89 billion, a P/E ratio of 18.24 and a beta of 0.81. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.
About Genmab A/S
Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.
Read More
- Five stocks we like better than Genmab A/S
- Macy’s Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
